Biocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer

Stock Information for Biocept Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biocept Inc.

Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide(TM) Assay to Evaluate Patients with Leptomeningeal Metastases
Biocept Signs CNSide(TM) Licensing Agreement with Plus Therapeutics
Biocept to Participate in the H.C. Wainwright Global Investment Conference
Biocept to Hold Business Update Conference Call on August 30, 2023
Biocept Reports Second Quarter 2023 Financial Results
Biocept's CNSide(TM) Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
Biocept Announces the Passing of Board Chair M. Faye Wilson
Biocept Names Antonino Morales as President and Chief Executive Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.